Biologic Specimen and Data Repository Information Coordinating Center
Home > Studies > VATS

Resources Available

Specimens and Study Datasets

Materials Available

PLASMA 16,244
SERUM 14,124

Study Documents

PDF Data Dictionary (PDF - 520.4 KB)
Forms (HTML )

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message.

If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.

Viral Activation Transfusion Study (VATS)

Clinical Trials URL:
Study Type: Clinical Trial
Prepared on October 13, 2008
Last Updated on August 18, 2010
Study Dates: 1994-2001
Consent: Unrestricted Consent
Commercial Use Restrictions: No
NHLBI Division: DBDR
Collection Type: Open BioLINCC Study - See bottom of this webpage for request information


To compare the effects of leukoreduced and unmodified RBC transfusions on survival, complications of acquired immunodeficiency syndrome, and relevant laboratory markers in HIV-infected patients.


Allogeneic blood transfusions have immunomodulatory effects and have been associated with activation of human immunodeficiency virus (HIV) and cytomegalovirus (CMV) in vitro and of HIV in small pilot studies. Retrospective studies suggest that transfusions adversely affect the clinical course of HIV. Data in selected non-HIV-infected patients requiring blood transfusion have suggested clinical benefit with leukocyte-reduced red blood cells (RBCs).


A total of 531 persons infected with HIV and CMV, aged 14 years or older, who required transfusions for anemia; 259 received leukoreduced transfusions and 262 received unmodified transfusions (10 did not receive the planned transfusion).


No evidence of HIV, CMV, or cytokine activation was found following blood transfusion in patients with advanced HIV infection. Leukoreduction provided no clinical benefit in these patients. These data demonstrate the importance of conducting controlled studies of effects of leukoreduction in different patient populations, since smaller studies in other patient populations have suggested leukoreduction may be beneficial. (JAMA March 28, 2001; Vol 285, No. 12)